Severe psoriasis: beyond the skin, what are the risks of not treating the disease?;Psoriasis sévère, au-delà de la peau, quel est le risque à ne pas traiter ?

Annales de Dermatologie et de Venereologie

Volumn 135, Issue SUPPL. 5, 2008, Pages

  Bessis, D ^a  

^a UNIV MONTPELLIER   (France)

Author keywords

Comorbidity; Metabolic syndrome; Psoriasis

Indexed keywords

EFALIZUMAB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHOTREXATE; PIOGLITAZONE;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG USE; HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; PSORIASIS; AUTOIMMUNE DISEASE; HEART INFARCTION; METABOLIC DISORDER; OBESITY; PATHOPHYSIOLOGY; RISK FACTOR;

ATHEROSCLEROSIS; AUTOIMMUNE DISEASES; COMORBIDITY; DIABETES MELLITUS; HUMANS; INSULIN RESISTANCE; METABOLIC DISEASES; MYOCARDIAL INFARCTION; OBESITY; PSORIASIS; RISK FACTORS;

EID: 55249123801     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0151-9638(08)73672-X     Document Type: Article

References (26)

1. Mrowietz U., Elder J.T., and Barker J. The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch Dermatol Res 298 (2006) 309-319
2. Abou-Samra T., Constantin J.M., Amarger S., Mansard S., Souteyrand P., Bazin J.E., et al. Generalized pustular psoriasis complicated by acute respiratory distress syndrome. Br J Dermatol 150 (2004) 353-356
3. Woo W.K., McMillan S.A., Watson R.G., McCluggage W.G., Sloan J.M., and McMillan J.C. Coeliac disease-associated antibodies correlate with psoriasis activity. Br J Dermatol 151 (2004) 891-894
4. McDonald C.J., and Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol 99 (1978) 469-475
5. Henseler T., and Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 32 (1995) 982-986
6. Boursier V. Le syndrome métabolique. J Mal Vasc 31 (2006) 190-201
7. Gisondi P., Tessari G., Conti A., Piaserico S., Schianchi S., Peserico A., et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 157 (2007) 68-73
8. Cohen A.D., Gilutz H., Henkin Y., Zahger D., Shapiro J., Bonneh D.Y., et al. Psoriasis and the metabolic syndrome. Acta Derm Venereol 87 (2007) 506-509
9. Sterry W., Strober B.E., Menter A., and on behalf of the International Psoriasis Council. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 157 (2007) 649-655
10. Herron M.D., Hinckley M., Hoffman M.S., Papenfuss J., Hansen C.B., Callis K.P., et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 141 (2005) 1527-1534
11. Mease P.J., Goffe B.S., Metz J., VanderStoep A., Finck B., and Burge D.J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356 (2000) 385-390
12. Krueger G.G., Papp K.A., Stough D.B., Loven K.H., Gulliver W.P., Ellis C.N., and Alefacept Clinical Study Group. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 47 (2002) 821-833
13. Krueger G.G., and Duvic M. Epidemiology of psoriasis: clinical issues. J Invest Dermatol 102 (1994) 14S-18S
14. Gelfand J.M., Neimann A.L., Shin D.B., Wang X., Margolis D.J., and Troxel A.B. Risk of myocardial infarction in patients with psoriasis. JAMA 296 (2006) 1735-1741
15. Ludwig R.J., Herzog C., Rostock A., Ochsendorf F.R., Zollner T.M., Thaci D., et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 156 (2007) 271-276
16. Boehncke S., Thaci D., Beschmann H., Ludwig R.J., Ackermann H., Badenhoop K., et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol 157 (2007) 1249-1251
17. Shapiro J., Cohen A.D., David M., Hodak E., Chodik G., Viner A., et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 56 (2007) 629-634
18. Naldi L., Chatenoud L., Linder D., Belloni Fortina A., Peserico A., Virgili A.R., et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 125 (2005) 61-67
19. Sampogna F., Tabolli S., and Abeni D. IDI Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) investigators. The impact of changes in clinical severity on psychiatric morbidity in patients with psoriasis: a follow-up study. Br J Dermatol 157 (2007) 508-513
20. Kirby B., Richards H.L., Mason D.L., Fortune D.G., Main C.J., and Griffiths C.E. Alcohol consumption and psychological distress in patients with psoriasis. Br J Dermatol 158 (2008) 138-140
21. Namazi M.R. Statins: novel additions to the dermatologic arsenal?. Exp Dermatol 13 (2004) 337-339
22. Shirinsky I.V., and Shirinsky V.S. Efficacy of simvastatin in plaque psoriasis: A pilot study. J Am Acad Dermatol 57 (2007) 529-531
23. Shafiq N., Malhotra S., Pandhi P., Gupta M., Kumar B., and Sandhu K. Pilot trial: Pioglitazone versus placebo in patients with plaque psoriasis (the P6). Int J Dermatol 44 (2005) 328-333
24. Prodanovich S., Ma F., Taylor J.R., Pezon C., Fasihi T., and Kirsner R.S. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 52 (2005) 262-267
25. Dominguez H., Storgaard H., Rask-Madsen C., Steffen Hermann T., Ihlemann N., Baunbjerg Nielsen D., et al. Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 42 (2005) 517-525
26. Bernstein L.E., Berry J., Kim S., Canavan B., and Grinspoon S.K. Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med 166 (2006) 902-908